Skip to content

Study · Randomized controlled trial · n = 40 · 2022

5 results

Effects of liraglutide vs. lifestyle changes on soluble suppression of tumorigenesis-2 (sST2) and galectin-3 in obese subjects with prediabetes or type 2 diabetes after comparable weight loss.

Simeone P, Tripaldi R, Michelsen A, Ueland T, Liani R, Ciotti S, Birkeland KI, Gulseth HL, Di Castelnuovo A, Cipollone F, Aukrust P, Consoli A, Halvorsen B, Santilli F

Cardiovascular diabetology11 Mar 2022Cited by 13 (Europe PMC)

PMID35277168 (opens in a new tab)PMCIDPMC8917620 (opens in a new tab)DOI10.1186/s12933-022-01469-w (opens in a new tab)PepBankPUB-35277168
Download PDFPubMedAsk about this study
Jump to 5 results

Summary

BackgroundSoluble suppression of tumorigenesis-2 (sST2) and galectin (Gal)-3 are two biomarkers related to inflammation, metabolic disturbances and to myocardial fibrosis that characterize several cardiac pathological conditions. Increased circulating levels of these molecules have been associated with risk of cardiovascular death. Treatment with liraglutide, a glucagon-like peptide 1 analog, is associated with weight loss, improved glycemic control, and reduced cardiovascular risk. We wanted to assess (I) potential differences between subjects with prediabetes or type 2 diabetes mellitus (T2DM) and healthy controls in sST2 and Gal-3 circulating levels, and their relationship with glycemic control and markers of beta cell function and myocardial injury; (II) whether liraglutide treatment modulates these markers in subjects with prediabetes or early T2DM independently of weight loss; (III) whether baseline levels of any of these two molecules may predict the response to liraglutide treatment.MethodsForty metformin-treated obese subjects (BMI ≥ 30) with prediabetes [impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) or both (n = 23)] or newly diagnosed T2DM (n = 17), were randomized to liraglutide or lifestyle counseling until achieving a comparable weight loss (7% of initial body weight). Thirteen subjects were enrolled as healthy controls for baseline sST2 and Gal-3 levels.ResultsBaseline sST2 levels were comparable between controls and obese patients (p = 0.79) whereas Gal-3 levels were significantly higher in patients as compared to controls (p < 0.001). Liraglutide treatment, but not weight loss achieved by lifestyle counseling, decreased plasma sST2 levels (- 9%, beta = - 14.9, standard deviation 6.9, p = 0.037) while Gal-3 levels did not change. A reduction in serum hs-Troponin I was observed after intervention, due to a 19% (p = 0.29) increase in the lifestyle arm, and a 25% decrease (p = 0.033) in the liraglutide arm (between-group difference p = 0.083). Lower baseline Gal-3 levels predicted a better improvement in beta cell function after liraglutide treatment.ConclusionsLiraglutide-induced reduction in sST2 and possibly hs-TnI suggests that in obese patients with prediabetes or early T2DM this drug may have a positive effect on (cardiac) fibrosis, whereas plasma level of Gal-3 before liraglutide initiation may predict response to the drug in terms of beta cell function improvement. Trial registration Eudract: 2013-001356-36.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In obese adults with prediabetes or type 2 diabetes, liraglutide decreased plasma sST2 by 9%, whereas weight loss through lifestyle counseling did not.

    In plain wordsIn obese adults with prediabetes or diabetes, liraglutide lowered a heart-stress marker (sST2); weight loss from lifestyle counseling did not.

    Peptide
    Liraglutide
    Outcome
    DecreasePlasma sST2
    Study

    n = 40

    Comparator
    Lifestyle counseling
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    sST2 decrease
    9%
    liraglutide

    Source sentences

    Summary
    Liraglutide treatment, but not weight loss achieved by lifestyle counseling, decreased plasma sST2 levels (- 9%, beta = - 14.9, standard deviation 6.9, p = 0.037) while Gal-3 levels did not change.
    1 context sentence
    Summary · context
    Forty metformin-treated obese subjects (BMI ≥ 30) with prediabetes [impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) or both (n = 23)] or newly diagnosed T2DM (n = 17), were randomized to liraglutide or lifestyle counseling until achieving a comparable weight loss (7% of initial body weight).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In obese adults with prediabetes or type 2 diabetes, liraglutide did not change Gal-3 levels.

    In plain wordsIn obese adults with prediabetes or diabetes, liraglutide did not change levels of the marker Gal-3.

    Peptide
    Liraglutide
    Outcome
    No significant changeGalectin-3 (Gal-3) levels
    Study

    n = 40

    Comparator
    Lifestyle counseling
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    while Gal-3 levels did not change.
    1 context sentence
    Summary · context
    Forty metformin-treated obese subjects (BMI ≥ 30) with prediabetes [impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) or both (n = 23)] or newly diagnosed T2DM (n = 17), were randomized to liraglutide or lifestyle counseling until achieving a comparable weight loss (7% of initial body weight).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In obese adults with prediabetes or type 2 diabetes, serum hs-Troponin I fell by 25% in the liraglutide arm.

    In plain wordsIn obese adults with prediabetes or diabetes, a heart-injury marker (troponin I) fell by 25% in the liraglutide group.

    Peptide
    Liraglutide
    Outcome
    DecreaseSerum hs-Troponin I change in the liraglutide arm
    Study

    n = 40

    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    hs-TnI decrease
    25%
    liraglutide arm

    Source sentences

    Summary
    a 25% decrease (p = 0.033) in the liraglutide arm
    1 context sentence
    Summary · context
    Forty metformin-treated obese subjects (BMI ≥ 30) with prediabetes [impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) or both (n = 23)] or newly diagnosed T2DM (n = 17), were randomized to liraglutide or lifestyle counseling until achieving a comparable weight loss (7% of initial body weight).
  4. 04HumanRandomized controlled trialEfficacy outcome

    In obese adults with prediabetes or type 2 diabetes, the between-group difference in hs-Troponin I between liraglutide and lifestyle counseling was not significant (p = 0.083).

    In plain wordsIn obese adults with prediabetes or diabetes, troponin I did not differ significantly between the liraglutide and lifestyle groups.

    Peptide
    Liraglutide
    Outcome
    No significant changeSerum hs-Troponin I, liraglutide versus lifestyle
    Study

    n = 40

    Comparator
    Lifestyle counseling
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Between-group difference P
    0.083
    liraglutide vs lifestyle

    Source sentences

    Summary
    between-group difference p = 0.083).
    1 context sentence
    Summary · context
    Forty metformin-treated obese subjects (BMI ≥ 30) with prediabetes [impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) or both (n = 23)] or newly diagnosed T2DM (n = 17), were randomized to liraglutide or lifestyle counseling until achieving a comparable weight loss (7% of initial body weight).
  5. 05HumanRandomized controlled trialOther

    In obese adults with prediabetes or type 2 diabetes, lower baseline Gal-3 levels predicted a better improvement in beta cell function after liraglutide.

    In plain wordsIn obese adults with prediabetes or diabetes, lower starting Gal-3 levels were linked to better beta cell function after liraglutide.

    Peptide
    Liraglutide
    Outcome
    Not applicableBaseline Gal-3 as predictor of beta cell function improvement
    Study

    n = 40

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Lower baseline Gal-3 levels predicted a better improvement in beta cell function after liraglutide treatment.
    1 context sentence
    Summary · context
    Forty metformin-treated obese subjects (BMI ≥ 30) with prediabetes [impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) or both (n = 23)] or newly diagnosed T2DM (n = 17), were randomized to liraglutide or lifestyle counseling until achieving a comparable weight loss (7% of initial body weight).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.